Pittsburgh, PA — March 16, 2025— Heart Input Output Inc. (“HEARTio”), an artificial intelligence healthcare diagnostics company, today announced the closing of $4.25 Million in new seed financing with participation from Intelligence Ventures, Audacious Capital, VU Venture Partners, LifeX (Pittsburgh), Bessel, and others. These funds will enable the launch of HEARTio’s pivotal study seeking FDA clearance for HEARTio’s flagship product, ECGio.
“This successful round of financing is a testament to the momentum we are building in bringing ECGio to market,” said Utkars Jain, Co-founder and CEO of HEARTio. “Up and down the cap table, we have so many people that believe in us from all around the world — executives, physicians, venture capitalists, and family offices. With this financing, we expect to complete our pivotal study, and submit the technology to the FDA for clearance. Our technology has the potential to democratize cardiovascular care and help create a world where no one experiences a heart attack.”
“In addition to our investors, we have been incredibly lucky to work with so many globally renowned experts in Cardiology, Emergency Medicine, Cardiothoracic Surgery, Medical Devices, Biostats, Life Science Tools, and more,” said Adam Butchy, Co-founder of HEARTio. “This amazing team has allowed us to stay focused on patient care and technological innovation, making sure that we are creating something that is truly disruptive and impactful.”
HEARTio is a digital diagnostics company using AI to detect coronary artery disease (CAD), more quickly, more accurately, and at a lower cost as compared to the current standard of care. HEARTio’s flagship product, ECGio, is an AI platform that analyzes the electrocardiogram (ECG) to predict coronary occlusion non-invasively. ECGio’s 1st validation study was published in the Canadian Journal of Cardiology “Deep Learning Algorithm Predicts Angiographic Coronary Artery Disease in Stable Patients Using Only a Standard 12-Lead Electrocardiogram” and a 2nd validation study on 16,000+ patients, “Use of Electrocardiograms to Identify Coronary Artery Disease: Cross-Validation of an Artificial Intelligence Model,” was recently published in JACC Advances.
About HEARTio
HEARTio is an AI-enabled cardiac diagnostics company revolutionizing how heart disease is detected and monitored. With a mission to make early detection scalable and accessible, HEARTio leverages cutting-edge deep learning to deliver faster, smarter, and more affordable insights to healthcare providers. Since its founding it has grown to incorporate John Marous as its Executive Chairman and Jake Fisher and John Moran as its co-Chief Commercialization Officers. For media inquiries, please contact: Michael Leasure, Co-Founder, President & COO Michael.Leasure@heartio.ai 610-451-7343
